Janet Hammond

2.6k total citations
50 papers, 1.7k citations indexed

About

Janet Hammond is a scholar working on Epidemiology, Infectious Diseases and Critical Care and Intensive Care Medicine. According to data from OpenAlex, Janet Hammond has authored 50 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Epidemiology, 16 papers in Infectious Diseases and 11 papers in Critical Care and Intensive Care Medicine. Recurrent topics in Janet Hammond's work include Nosocomial Infections in ICU (10 papers), Hepatitis C virus research (10 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). Janet Hammond is often cited by papers focused on Nosocomial Infections in ICU (10 papers), Hepatitis C virus research (10 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). Janet Hammond collaborates with scholars based in United States, South Africa and United Kingdom. Janet Hammond's co-authors include Peter D. Potgieter, Robert K. Pelz, Sandra M. Swoboda, Pamela A. Lipsett, Craig W. Hendrix, Marie Diener‐West, Frederick G. Hayden, Oliver N. Keene, William G. Merz and Michael J. Elliott and has published in prestigious journals such as New England Journal of Medicine, Hepatology and Annals of Surgery.

In The Last Decade

Janet Hammond

45 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janet Hammond United States 20 975 697 277 196 143 50 1.7k
Bertrand Gachot France 24 1.2k 1.2× 906 1.3× 331 1.2× 371 1.9× 68 0.5× 80 2.1k
Sigfrido Rangel-Frausto Mexico 13 629 0.6× 511 0.7× 294 1.1× 210 1.1× 100 0.7× 35 1.4k
Ernesto G. Scerpella United States 16 476 0.5× 527 0.8× 242 0.9× 71 0.4× 93 0.7× 28 1.1k
Athanassios Skoutelis Greece 11 640 0.7× 246 0.4× 131 0.5× 146 0.7× 107 0.7× 19 1.5k
José Bordón United States 24 1.3k 1.4× 376 0.5× 196 0.7× 234 1.2× 147 1.0× 69 2.1k
I. M. Hoepelman Netherlands 24 698 0.7× 307 0.4× 94 0.3× 121 0.6× 69 0.5× 66 1.4k
Diego Viasus Spain 31 1.4k 1.5× 585 0.8× 265 1.0× 228 1.2× 103 0.7× 84 2.3k
Javier Ena Spain 24 610 0.6× 630 0.9× 77 0.3× 84 0.4× 84 0.6× 102 1.7k
Frederic Gómez‐Bertomeu Spain 21 790 0.8× 341 0.5× 246 0.9× 153 0.8× 91 0.6× 73 1.6k
Ronan Boulmé France 9 543 0.6× 245 0.4× 340 1.2× 74 0.4× 64 0.4× 17 951

Countries citing papers authored by Janet Hammond

Since Specialization
Citations

This map shows the geographic impact of Janet Hammond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Hammond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Hammond more than expected).

Fields of papers citing papers by Janet Hammond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet Hammond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Hammond. The network helps show where Janet Hammond may publish in the future.

Co-authorship network of co-authors of Janet Hammond

This figure shows the co-authorship network connecting the top 25 collaborators of Janet Hammond. A scholar is included among the top collaborators of Janet Hammond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Hammond. Janet Hammond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Winchester, Lee C., et al.. (2024). Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19. Journal of Antimicrobial Chemotherapy. 79(6). 1423–1431. 1 indexed citations
2.
Lickliter, Jason D., et al.. (2024). First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. Antimicrobial Agents and Chemotherapy. 68(5). e0161523–e0161523. 6 indexed citations
3.
Gane, Edward, Paul J. Pockros, Stefan Zeuzem, et al.. (2014). Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM ‐ SVR study. Liver International. 35(1). 79–89. 23 indexed citations
4.
Malan, Daniel R, et al.. (2008). Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 47(2). 161–167. 114 indexed citations
5.
Gravenstein, Stefan, Paul J. Drinka, Dan Osterweil, et al.. (2005). Inhaled Zanamivir Versus Rimantadine for the Control of Influenza in a Highly Vaccinated Long-term Care Population. Journal of the American Medical Directors Association. 6(6). 359–366. 38 indexed citations
6.
Hendrix, Craig W., Janet Hammond, Sandra M. Swoboda, et al.. (2001). Surveillance Strategies and Impact of Vancomycin-Resistant Enterococcal Colonization and Infection in Critically Ill Patients. Annals of Surgery. 233(2). 259–265. 38 indexed citations
7.
Pelz, Robert K., Craig W. Hendrix, Sandra M. Swoboda, et al.. (2001). Double-Blind Placebo-Controlled Trial of Fluconazole to Prevent Candidal Infections in Critically Ill Surgical Patients. Annals of Surgery. 233(4). 542–548. 231 indexed citations
8.
Hedrick, James, Asher Barzilai, Ulrich Behre, et al.. (2000). Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. The Pediatric Infectious Disease Journal. 19(5). 410–417. 176 indexed citations
9.
Hayden, Frederick G., Larisa V. Gubareva, Arnold S. Monto, et al.. (2000). Inhaled Zanamivir for the Prevention of Influenza in Families. New England Journal of Medicine. 343(18). 1282–1289. 262 indexed citations
10.
Pelz, Robert K., Pamela A. Lipsett, Sandra M. Swoboda, et al.. (2000). The Diagnostic Value of Fungal Surveillance Cultures in Critically Ill Patients. Surgical Infections. 1(4). 273–281. 35 indexed citations
11.
Potgieter, Peter D., et al.. (1995). Cost of critical care in South Africa. South African Medical Journal. 85(5). 1 indexed citations
12.
Hammond, Janet, et al.. (1995). The Etiology and Antimicrobial Susceptibility Patterns of Microorganisms in Acute Community-Acquired Lung Abscess. CHEST Journal. 108(4). 937–941. 48 indexed citations
13.
Hammond, Janet & Peter D. Potgieter. (1995). Long-term effects of selective decontamination on antimicrobial resistance. Critical Care Medicine. 23(4). 637–645. 48 indexed citations
14.
15.
Hammond, Janet, et al.. (1994). Microbiological surveillance during selective decontamination of the digestive tract (SDD). Journal of Antimicrobial Chemotherapy. 34(4). 529–544. 28 indexed citations
16.
Hammond, Janet, et al.. (1993). Severe Pneumococcal Pneumonia Complicated by Massive Pulmonary Gangrene. CHEST Journal. 104(5). 1610–1612. 33 indexed citations
17.
Hammond, Janet & Peter D. Potgieter. (1993). Neurologic Disease Requiring Long-term Ventilation. CHEST Journal. 104(2). 547–551. 9 indexed citations
18.
Potgieter, Peter D. & Janet Hammond. (1992). Etiology and Diagnosis of Pneumonia Requiring ICU Admission. CHEST Journal. 101(1). 199–203. 79 indexed citations
19.
Hammond, Janet, et al.. (1991). Intensive care management of community-acquired Klebsiella pneumoniae. Respiratory Medicine. 85(1). 11–16. 8 indexed citations
20.
Hammond, Janet, et al.. (1990). Influence of amikacin as the primary aminoglycoside on bacterial isolates in the intensive care unit. Critical Care Medicine. 18(6). 607–610. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bertrand Gachot Breakdown of academic impact, for papers by Sigfrido Rangel-Frausto Breakdown of academic impact, for papers by Ernesto G. Scerpella Breakdown of academic impact, for papers by Athanassios Skoutelis Breakdown of academic impact, for papers by José Bordón Breakdown of academic impact, for papers by I. M. Hoepelman Breakdown of academic impact, for papers by Diego Viasus Breakdown of academic impact, for papers by Javier Ena Breakdown of academic impact, for papers by Frederic Gómez‐Bertomeu Breakdown of academic impact, for papers by Ronan Boulmé
Rankless by CCL
2026